Dr Dinh Bui is a senior research fellow at Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, the University of Melbourne. His research focuses on lifetime risk factors for lung function trajectories and COPD.

Angela is a physiotherapist at the Alfred Hospital and research fellow in the Central Clinical School at Monash University

Stanley's research focuses on COPD and comorbid conditions like muscle dysfunction. He is driven by the aspiration to establish reliable biomarkers and develop promising therapeutic strategies for treating comorbid diseases such as skeletal muscle dysfunction, to enhance the quality of life for the individuals with COPD.

Professor of Clinical Pharmacology & Respiratory Medicine at the University of Manchester. His research interest is the development of new drugs for asthma and COPD, acting as PI in >400 clinical trials. He is a member of the GOLD committee, and fellow of ERS and BPS with >400 publications.

Paul King is a respiratory physician based at Monash Health/Monash University. He has a longstanding research interest in lung inflammation. Recently he has concentrated on the pathway of phagocyte extracellular traps and how this pathway can be targeted by therapeutics such as alpha-1 antitrypsin

Dr Lu is a Postdoctoral Researcher with the Respiratory Translational Research Group at University of Tasmania. Her research pursuits involve gaining insights into the pathogenesis of chronic respiratory diseases, including COPD, IPF, lung cancer, and Asthma-COPD overlap (ACO), also actively examining the impact of vaping on human lung cellular changes.

Professor Price is the Founder and Head of the Observational and Pragmatic Research Institute (OPRI) in Singapore. Additionally, Professor Price is the Head of Optimum Patient Care (OPC) Global in Australia and the UK, a social enterprise focused on disease registries and quality improvement in healthcare. He established the Optimum Patient Care Research Database (OPCRD), which holds data from over 1100 general practices and 19.5 million patients in the UK. Professor Price leads the International Severe Asthma Registry (ISAR) and the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care (CONQUEST) registries.

Dr Sohal is Head of the Respiratory Translational Research Group at the University of Tasmania, Launceston, and internationally recognized leader in chronic lung disease. His research group is focused on discovering and identifying novel mechanisms that may act as exciting new therapeutic targets for treating chronic lung diseases, such as COPD, lung cancer, asthma-COPD overlap, pulmonary hypertension and ILDs. His lab is also home to investigations regarding effects of electronic smoking devices on lung health. Dr Sohal’s work has been noted in the WHO documents informing global policy. He has been the Board Director TSANZ, and President TSANZ Tasmania Branch. Dr Sohal has been appointed Deputy Chair by the ERS for the Molecular Pathology and Functional Genomics Group.